Natural Killer Cell Function

Your immune system has a frontline strike team called natural killer cells, or NK cells. They patrol your blood looking for cells that have turned cancerous or been hijacked by viruses, and they kill those cells on contact. A standard immune panel can count how many NK cells you have. It cannot tell you whether those cells can actually fight.

This test goes further. It measures NK cell function, usually by stimulating your blood sample and seeing how much interferon-gamma, a key immune signaling molecule, your NK cells release. The number reflects whether your innate immune defense is firing on all cylinders or running cold.

What This Test Actually Measures

NK cell function (also called NK cell activity, or NKA) is not a protein, hormone, or metabolite. It is a functional readout. The lab stimulates your NK cells in a tube and measures either the amount of IFN-gamma (interferon-gamma) they release over about 24 hours, or how effectively they kill target cells in a cytotoxicity assay.

NK cells come in two main flavors in blood. About 90% are the CD56dim subset, which does most of the killing. The smaller CD56bright subset specializes in producing inflammatory signals. These are useful simplifications: CD56dim cells can also produce cytokines when strongly activated, and CD56bright cells can kill under certain conditions. A functional test captures the combined output of these populations, which is something a simple cell count cannot do.

Because this is a functional measurement, the result depends on the specific assay your lab uses. Different stimulation methods, target cells, and readouts produce different numbers. This is a research-stage marker without universally standardized cutpoints, so the trend in your own results over time matters more than comparing your value to anyone else's.

Cancer Surveillance

NK cells are part of your body's natural anti-cancer defense. They recognize cells that have lost their normal surface markers, a sign of malignant transformation, and destroy them before tumors take hold. When NK function drops, this surveillance weakens.

In a high-risk lung cancer cohort, people with late-stage disease had stimulated NK activity of about 161 pg/mL of IFN-gamma compared to about 450 pg/mL in controls, roughly 64% lower. In another non-small cell lung cancer study, low NK activity correctly identified disease with 91% specificity, though sensitivity was only 52%, meaning it caught about half of cases. In prostate cancer, stimulated NK activity averaged 431 pg/mL in men with cancer versus 975 pg/mL in controls, a difference of roughly 56%.

A long-term study of 3,625 Japanese adults followed for 11 years found that lower NK cytotoxic activity was associated with higher overall cancer risk. The statistically significant link was driven largely by women and the combined-sex analysis; in men alone, the trend was present but did not reach statistical significance. This supports the idea that NK function reflects ongoing immune surveillance, though it does not prove that boosting NK function in a healthy person prevents cancer.

Metabolic Health and Type 2 Diabetes

Blood sugar problems track with weaker NK function. In a study comparing adults with type 2 diabetes, prediabetes, and normal glucose tolerance, NK activity in the diabetes group averaged 768 units versus about 2,400 in both the prediabetes and normal groups, roughly 68% lower. Within the diabetes group, NK activity fell as fasting glucose, HbA1c (a three-month average of blood sugar), and post-meal glucose rose.

HbA1c was an independent predictor of NK activity, meaning the link held even after accounting for other variables. The takeaway is that metabolic dysfunction is not just a circulatory problem. It quietly degrades the immune system's killing capacity, which may help explain why people with diabetes have higher rates of infections and certain cancers.

Suspected Hemophagocytic Lymphohistiocytosis (HLH)

HLH is a rare and dangerous condition where the immune system goes into overdrive but cannot properly kill its targets. Defective NK cytotoxicity has historically been a hallmark. In an adult HLH cohort, NK cytotoxicity averaged 12.1% versus 24.3% in non-HLH patients with similar fevers and cytopenias, about half the killing capacity.

NK cytotoxicity correctly flagged 96 out of 100 HLH cases (96% sensitivity), but it also flagged many non-HLH cases (36% specificity), so it is most useful for ruling HLH out. Specificity rose to 94% when low NK activity was combined with very high ferritin, an iron-storage protein that spikes in HLH. Practice is evolving here: the updated HLH-2024 diagnostic criteria from the Histiocyte Society have removed NK cell activity from the formal criteria in favor of genetic testing and other lymphocyte cytotoxicity assays, and North American (NACHO) guidance now prefers degranulation assays such as CD107a mobilization over NK function for the workup. In adults with secondary HLH, NK cytotoxicity may also not reliably distinguish HLH from non-HLH disease controls. NK function testing can still add information, but it is no longer considered the central diagnostic test it once was.

Autoimmune and Inflammatory Conditions

NK cell abnormalities are reported across many autoimmune conditions, including systemic lupus erythematosus (SLE, a multi-organ autoimmune disease), rheumatoid arthritis, multiple sclerosis, type 1 diabetes, and systemic sclerosis. In active SLE, NK cytotoxicity is reduced but NK cells produce excess IFN-gamma when triggered, a dysregulated rather than simply weak pattern.

In systemic sclerosis, blood NK cell counts are decreased, and lower counts have been linked to pulmonary arterial hypertension (high blood pressure in the lung arteries), a serious complication. The pattern in autoimmunity is rarely a clean drop or rise. It is usually dysregulation: some functions impaired while others run hot.

Reproductive Health

In women with recurrent pregnancy loss or repeated implantation failure during IVF, blood NK testing is sometimes used to look for immune dysfunction. A combination of regulatory T cell, T follicular helper 17 cell, and inhibitory NK cell markers correctly classified recurrent implantation failure with an area under the curve of 0.900, a strong combined signal.

Activation-based blood NK tests are generally preferred over simple counts in this setting, but the clinical utility of peripheral blood NK testing in recurrent pregnancy loss remains controversial. Systematic reviews have found no clear correlation between peripheral blood NK levels and uterine NK levels, and the activity in the uterus is what matters most for implantation. The evidence here is most useful as part of a specialist workup, not as a routine fertility screen.

Acute Infection and Severe Illness

NK function rises during acute infection, then often falls as the illness drags on. In scrub typhus, a mite-borne bacterial infection, circulating NK cells were higher and more activated, and stimulated IFN-gamma production increased. Higher NK levels tracked with worse disease severity.

In severe COVID-19, NK cells became hyperactivated early but showed exhaustion in ICU patients, with defective IFN-gamma production when re-stimulated. A high reading during acute illness does not mean a robust immune system. It often means an immune system in overdrive that may collapse later.

Reading the Direction of the Number

Higher NK function is not automatically better, and lower is not automatically worse. In a healthy state, you want strong cytotoxic capacity ready to deploy on demand. In active infection, very high circulating NK activation can reflect severity. In autoimmune disease, dysregulation matters more than the raw direction.

This is a phenotype marker, not a simple good-number-bad-number lab. Interpretation depends on the clinical setting. A low value in an otherwise healthy adult raises questions about immune surveillance. A high value during acute illness raises questions about inflammation, not strength.

Why One Reading Is Not Enough

NK function is dynamic. It shifts with sleep, exercise, infection, surgery, medications, and stress. A single value can be misleading. Tracking your trend over time gives you something a one-time snapshot never will: a sense of your normal range and a way to see whether interventions are actually moving the needle.

For a proactive baseline, get an initial reading when you are healthy and not recovering from recent illness or hard exercise. If you are making lifestyle changes or starting an intervention aimed at immune support, retest in 3 to 6 months. If you are stable, at least once a year. Pair every test with notes on recent illness, medications, and exercise so you can interpret shifts in context.

When Results Can Be Misleading

Several short-term factors can distort a single reading without indicating any real change in your immune health:

• Recent intense exercise: NK activity can rise sharply right after vigorous exercise. A 2021 systematic review and meta-analysis of 12 studies found that pooled NK cytolytic activity returns to pre-exercise levels within about 1 to 2 hours of recovery and does not consistently drop below baseline, though some individual studies have reported a brief dip. To be safe, a 24-hour washout after a hard workout is a reasonable precaution before testing.
• Recent surgery: Postoperative NK cell number and cytotoxicity drop sharply in the hours after surgery, with incomplete recovery at 24 hours. This is driven by both surgical stress and the medications used.
• Acute illness or fever: Active infection can either spike or suppress NK readings depending on the stage. A reading taken while you are sick is not a reading of your true baseline.
• Assay variation: Different labs use different stimulation protocols and target cells. Values from one method are not directly comparable to another, which is one reason serial testing at the same lab matters.

Some medications also shift the number without representing a true change in immune competence at the disease level. Perioperative opioids and anesthetics (fentanyl, morphine, propofol, oxycodone), rituximab and other cancer immunochemotherapies, and azathioprine (an immunosuppressant) all lower blood NK readings during treatment. If you are on any of these and want a representative baseline, the timing of your draw matters.

What to Do With an Unexpected Result

If your NK function comes back unexpectedly low or high, do not draw a conclusion from a single number. Retest after a few weeks once you are well-rested, free of acute illness, and at least 24 hours past hard exercise. Look at the pattern across at least two or three readings.

Pair the result with companion tests that put it in context. A complete blood count with differential shows whether overall lymphocyte numbers are off. High-sensitivity CRP and ferritin gauge ongoing inflammation. HbA1c and fasting glucose check whether metabolic dysfunction is dragging down immune capacity. Vitamin D and zinc status can affect NK readings. If your result is persistently abnormal and unexplained, that is the point to bring it to a clinician who works with immune function, such as an immunologist or, depending on context, an oncologist, rheumatologist, or reproductive immunologist.

Use this test for what it is good at: detecting shifts in your innate immune capacity over time, especially when you have a reason to monitor it. It is not a definitive screen for any single disease, and a normal reading does not rule out cancer, autoimmunity, or infection. It adds a layer of information that count-based immune panels miss.